Vor Biopharma stock holds price target, buy rating on positive study data

Retrieved on: 2024-09-07 09:10:54

Tags for this article:

Orphan drugs

Gemtuzumab ozogamicin

Hepatotoxins

Lintuzumab

Click the tags to see associated articles and topics

Vor Biopharma stock holds price target, buy rating on positive study data. View article details on hiswai:

Summary

The article outlines Vor Biopharma's promising clinical trial results for trem-cel and VCAR33ALLO, reflecting current market trends in orphan drugs. Tags highlight specific drugs linked to these market trends, including gemtuzumab ozogamicin and others.

Article found on: au.investing.com

View Original Article